Tag Archives: mosquitoes

On September 30, The Washington Post highlighted efforts in Haiti to eliminate lymphatic filariasis, commonly known as elephantiasis. A neglected tropical disease (NTD), elephantiasis is a parasitic infection spread by mosquitoes that can lead to swelling of the arms or legs — sometimes severely enough that individuals with the disease are stigmatized or unable to work. The good news is that elephantiasis can be prevented with anti-parasitic medicines. The Centers for Disease Control and Prevention and the U.S. Agency for International Development’s NTD program have taken a leadership role in administering these drugs in countries that are affected by elephantiasis. U.S. public health professionals have joined forces with local public health professionals and helped to organize programs, provide technical assistance and monitor progress. Through the collaborative efforts of these invaluable individuals, nine countries have already been declared free of elephantiasis. With support from the CDC and international charities, the Haitian health ministry is working hard to distribute this life-saving medication and join the list of countries free of elephantiasis.

This kind of outstanding work by public health professionals happens every day all around the world. Although there is no risk of elephantiasis in America, there are other NTDs emerging in the U.S. such as Chagas disease, West Nile virus and dengue fever. The CDC and other public health professionals play a crucial role in treating these diseases and organizing prevention and education campaigns here at home. These tireless individuals keep our drinking water safe, our air clean and our children healthy. Please join Research!America and other public health organizations in recognizing these public health heroes on November 19 for Public Health Thank You Day. For more information or to learn how you can get involved, please visit www.researchamerica.org/ph_thank_you or like our PHTD Facebook page at www.facebook.com/PHTD1.

As reported in the Washington Post, the number of West Nile virus cases in the U.S. is on the rise. Traditionally a disease that affects people in Africa, the Middle East and Asia, 48 states in the U.S. have reported cases in 2012 alone. Nearly 2,000 cases and 87 deaths, including one Wednesday in DC, have been reported overall. The West Nile virus, a neglected tropical disease or NTD, can cause flu-like symptoms or, in severe cases, even brain damage.

Peter Hotez, MD, PhD, director of the Texas-based product development partnership Sabin Vaccine Institute, recently wrote a New York Times op-ed addressing the increasing thread of West Nile right here in the U.S., “Tropical Disease: The New Plague of Poverty.” As Hotez points out, West Nile is just one of several NTDs that have a presence in the United States. Dengue fever, another virus transmitted through mosquitoes, has been reported in Texas, Florida and Hawaii. A recent estimate finds that 300,000 individuals in the U.S. have Chagas disease, an infection transmitted through insects that can cause heart failure and even sudden death. These NTDs pose an immediate threat to the health of Americans, particularly in impoverished areas of the South where poorer sanitation and drainage systems allow NTD “carriers” to thrive.

NTDs can go undocumented for long periods of time, can be extremely debilitating and have inflicted a large toll on peoples’ health and economic stability around the world. NTDs paint an increasingly troubling picture for American health. Toxic and ineffective, or in some cases no treatments, exist for many of these NTDs, and better surveillance and monitoring is desperately needed. With little financial incentive, private companies are reluctant to invest in this research. However, there is hope. Federally funded researchers at the National Institutes of Health have identified a new drug that has the potential to treat Chagas disease. Additional clinical trials will determine its safety and efficacy for widespread use. Bloomberg recently reported that another PDP, the Dengue Vaccine Initiative, has developed four dengue vaccines that are currently undergoing clinical trials. Continuing to fund this type of research and development is critical to ensuring that the promise of these vaccines becomes a reality.